NASDAQ: ABIO - ARCA biopharma, Inc.

六个月盈利: -36.84%
部门: Healthcare

促销时间表 ARCA biopharma, Inc.


关于公司

ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19.

更多详情
ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.

IPO date 1997-08-08
ISIN US00211Y5069
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 4.9E-5
Дивиденд ао 0.1285
Сайт https://www.arcabio.com
每日价格变化: 0% (2.4)
每周价格变化: 0% (2.4)
每月价格变化: 0% (2.4)
3个月内价格变化: 0% (2.4)
六个月内的价格变化: -36.84% (3.8)
每年价格变化: +40.35% (1.71)
3年内价格变化: +1.27% (2.37)
5年内价格变化: -53.03% (5.11)
10年价格变化: 0% (2.4)
年初以来价格变化: 0% (2.4)

低估

姓名 意义 年级
P/S 0 0
P/BV 0.6659 10
P/E 0 0
EV/EBITDA 1.71 10
全部的: 5

效率

姓名 意义 年级
ROA, % -14.1 0
ROE, % -14.42 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 66.25 10
DSI 1 10
全部的: 7.35

责任

姓名 意义 年级
Debt/EBITDA -0.0384 10
全部的: 8

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 7721.03 10
盈利能力 Ebitda, % 30.29 5
盈利能力 EPS, % -91.08 0
全部的: 3.2

股利, % 股利 根据期间结果 之前购买 登记截止日期 之前付款
504.1% 19.08 II кв. 2024 27.08.2024 29.08.2024 13.09.2024



导师 职称 支付 出生年份
Mr. Thomas A. Keuer President, COO & Principal Executive Officer 400.8k 1959 (66 年)
Mr. C. Jeffrey Dekker CPA CFO, Treasurer & Company Secretary 323.07k 1965 (60 年)

地址: United States, Westminster. CO, 10170 Church Ranch Way - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.arcabio.com